PTC THERAPEUTICS, INC.

PTC Therapeutics, Inc. announced the completion of its previously disclosed private offering of $550 million aggregate principal amount of 0.0% Convertible Senior Notes due 2031. The offering included the full exercise of the initial purchasers' option for an additional $50 million in notes. These unsecured senior obligations will not bear regular interest and mature on June 15, 2031, with an initial conversion price of approximately $107.48 per share.

PTC Therapeutics, Inc. announced the pricing of a $500.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2031. The company also granted initial purchasers an option to buy an additional $50.0 million in notes. Approximately $328.8 million of the net proceeds will be used to repurchase $222.0 million of its outstanding 1.5% Convertible Senior Notes due 2026, with the remaining proceeds for general corporate purposes and further repurchases of the 2026 notes.

PTC Therapeutics, Inc. announced that Alethia Young resigned from its Board of Directors, effective June 8, 2026. Ms. Young cited the need to focus on other work commitments as the reason for her departure, clarifying there were no disagreements with the company. She will continue to serve as an advisor to PTC Therapeutics under a consulting agreement, receiving a monthly fee of $4,166.67 for a term extending through June 8, 2027.

PTC Therapeutics reported a net loss of $2.8 million for Q1 2026, a significant decline from a net income of $866.6 million in Q1 2025, primarily due to the absence of a large collaboration payment. Total revenues fell by 76.8% to $272.6 million. Despite the financial downturn, the company announced positive 24-month interim results for votoplam in Huntington's disease, showing a 52% slowing of disease progression, and Novartis commenced a global Phase 3 study for the drug.

PTC Therapeutics announced positive topline results from the 24-month interim analysis of the PIVOT-HD long-term extension study for votoplam in Huntington's disease. The study demonstrated a favorable dose-dependent slowing of disease progression in Stage 2 participants, with a 52% slowing at the 10 mg dose and 28% at the 5 mg dose compared to a natural history cohort. The safety profile remained favorable, and Novartis has initiated the global Phase 3 INVEST-HD study for votoplam, which will enroll approximately 770 early-stage HD patients.